1. EGFR and cetuximab sensitivity of SCCUAT
EGFR and cetuximab sensitivity of SCCUAT. A, EGFR mRNA levels in biopsies from tumors of the indicated organs published at cBioPortal for Cancer Genomics (55, 56).
EGFR and cetuximab sensitivity of SCCUAT. A, EGFR mRNA levels in biopsies from tumors of the indicated organs published at cBioPortal for Cancer Genomics (55, 56). B, EGFR mRNA levels in commercial available cell lines originating from esophagus or head and neck published at cBioPortal for Cancer Genomics (55, 56). RMA, robust multiarray average. Arrows, EGFR gene amplification. *, cell lines included in the present study. C, immunoblot analyses of pEGFR(Tyr1068) and EGFR in selected SCCUAT cell lines. D, EGFR gene copy number normalized to Multicopy Reference, EGFR mRNA normalized to GAPDH, EGFR protein levels normalized to β-actin, and pEGFR(Tyr1068) levels normalized to β-actin. Quantification data of EGFR and pEGFR(Tyr1068) are presented as average of three independent experiments ±SEM. E, growth inhibition of selected SCCUAT cell lines in vitro induced by 50 μg/mL cetuximab after 96 hours of treatment using WST-1 in a viability assay. Mutation status for key oncogenes: black, mutation; gray, unknown mutation status; and white, wild-type. F, correlation blots of the level of cetuximab-induced growth inhibition vs. EGFR copy number, EGFR mRNA, EGFR protein expression, or pEGFR(Tyr1068) expression. The data have been normalized as described in D.
Ida Kjær et al. Mol Cancer Ther 2016;15:
©2016 by American Association for Cancer Research